Understanding the Market | PEGBIO CO-B surged over 20% in the closing session, reaching a new high, recently granting exclusive licensing for diabetes drugs in the Middle East and Africa
PEGBIO CO-B surged over 20% in late trading, reaching a high of HKD 62.25, setting a new record since its listing. As of the time of publication, it rose 16.51%, trading at HKD 60.3, with a transaction volume of HKD 30.2346 million. In terms of news, PEGBIO recently announced a strategic partnership with PDC FZ-LLC, a leading pharmaceutical research and development institution in the UAE, granting it exclusive rights to develop, distribute, market, and commercialize PEGBIO's core product Visepegenatide (PB-119) in the Middle East and Africa. This collaboration marks a key step in PEGBIO's global commercialization strategy. It is reported that Visepegenatide (PB-119) is a GLP-1 receptor agonist developed by PEGBIO for weekly subcutaneous injection, used for the treatment of type 2 diabetes and weight management. According to the International Diabetes Federation, the prevalence of diabetes among adults in the Middle East and North Africa is as high as 16.2%, ranking first in the world. This collaboration is expected to accelerate the availability of this innovative therapy, Visepegenatide (PB-119), to many patients in the region with unmet medical needs
According to Zhitong Finance APP, PEGBIO CO-B (02565) surged over 20% in late trading, reaching a high of HKD 62.25, setting a new record since its listing. As of the time of publication, it rose 16.51%, trading at HKD 60.3, with a transaction volume of HKD 30.2346 million.
In terms of news, PEGBIO recently announced a strategic cooperation with PDC FZ-LLC, a leading pharmaceutical research and development institution in the UAE, granting it exclusive rights to develop, distribute, market, and commercialize PEGBIO's core product Visepegenatide (PB-119) in the Middle East and Africa. This cooperation marks a key step in PEGBIO's global commercialization strategy.
It is reported that Visepegenatide (PB-119) is a GLP-1 receptor agonist developed by PEGBIO for once-weekly subcutaneous injection, used for the treatment of type 2 diabetes and weight management. According to the International Diabetes Federation, the prevalence of diabetes among adults in the Middle East and North Africa is as high as 16.2%, ranking first in the world. This cooperation is expected to accelerate the availability of this innovative therapy, Visepegenatide (PB-119), to many patients in the region with unmet medical needs
